{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:13:59Z","timestamp":1794870839479,"version":"4.9.1"},"reference-count":25,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Youth Fund of Zhongshan Hospital, Fudan University","award":["2024ZSQN03"],"award-info":[{"award-number":["2024ZSQN03"]}]},{"name":"The construction project of Shanghai Key Laboratory of Molecular Imaging","award":["KFKT-2024-01"],"award-info":[{"award-number":["KFKT-2024-01"]}]},{"name":"The construction project of Shanghai Key Laboratory of Molecular Imaging","award":["KFKT-2025-03"],"award-info":[{"award-number":["KFKT-2025-03"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"crossref","award":["82172002"],"award-info":[{"award-number":["82172002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"crossref","award":["82272058"],"award-info":[{"award-number":["82272058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"crossref","award":["82472037"],"award-info":[{"award-number":["82472037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Due to its high specificity and peak expression in hepatocellular carcinoma (HCC), Glypican-3 (GPC3) is a heavily researched target. While current GPC3-targeted therapies demonstrate remarkable efficacy, traditional GPC3 assessment methods are limited by time-dependent and spatial heterogeneity, invasiveness, and prolonged waiting periods, highlighting an urgent need for new GPC3 evaluation strategies. In this study, first, we selected MHCC97H as a GPC3-high expressing HCC cell line (named GPC3high MHCC97H) and constructed a GPC3-low expressing MHCC97H cell line (named GPC3low MHCC97H) using lentiviral transfection technology. Second, a novel radiopharmaceutical precursor, CS03, was synthesized. Molecular docking analysis revealed that CS03 exhibits the potential to bind to multiple amino acid residues of GPC3, indicating its promise as a targeting molecule for GPC3. Therefore, we labeled it with Ga-68 to synthesize [68Ga]Ga-CS03. The radiolabeling yield of [68Ga]Ga-CS03 exceeded 80%. After purification, the radiochemical purity of [68Ga]Ga-CS03 was greater than 98%, with a specific activity of (3.00 \u00b1 0.22) \u00d7 106 MBq\/mmol. [68Ga]Ga-CS03 exhibited excellent in vitro stability, rapid blood clearance (T1\/2\u03b1 = 0.93 \u00b1 0.49 min and T1\/2\u03b2 = 17.22 \u00b1 1.42 min), and good in vitro affinity (36.30 \u00b1 5.17 nM). Micro-PET\/CT imaging of HCC models revealed significant [68Ga]Ga-CS03 radiotracer accumulation in GPC3high MHCC97H tumors 0.5 h postinjection. In contrast, minimal or no significant accumulation was detected in GPC3low MHCC97H tumors and blocking group tumors, indicating the excellent in vivo affinity and specificity of [68Ga]Ga-CS03. [68Ga]Ga-CS03 showed rapid tumor clearance, with a significant decrease in tumor radiotracer distribution by 1 h, a finding corroborated by subsequent biodistribution studies. Furthermore, micro-PET\/CT images and biodistribution results indicated that [68Ga]Ga-CS03 was cleared by the kidneys, which explains its rapid blood clearance. Finally, we collected tumor tissues from the animal models after PET imaging and performed hematoxylin and eosin (H&amp;E) staining and GPC3 immunofluorescence (IF) staining. We found that the fluorescence intensity of IF staining was positively correlated with the radiotracer distribution in the tumor sites on PET images, which further validated the specificity of [68Ga]Ga-CS03 for GPC3 binding. In conclusion, we developed [68Ga]Ga-CS03, a novel GPC3-targeted PET radiotracer. Extensive in vitro and in vivo evaluations demonstrated its favorable stability, high affinity, and specificity. These promising preclinical findings highlight its potential for the noninvasive assessment of GPC3 expression in HCC.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00559","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:02:24Z","timestamp":1785934944000},"page":"4710-4718","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical\nEvaluation of [68Ga]Ga-CS03\nas a Novel GPC3-Targeted Probe for Imaging GPC3 in Hepatocellular\nCarcinoma Models"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3903-5713","authenticated-orcid":true,"given":"Dai","family":"Shi","sequence":"first","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]},{"name":"Zhongshan Hospital Fudan University , , ,","place":["Shanghai, China, 200032"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujian","family":"Mao","sequence":"additional","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Xie","sequence":"additional","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]},{"name":"Zhongshan Hospital Fudan University , , ,","place":["Shanghai, China, 200032"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2783-1341","authenticated-orcid":true,"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Applied Physics, Chinese Academy of Sciences , , ,","place":["Shanghai, China, 201800"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2886-3273","authenticated-orcid":true,"given":"Dengfeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Shanghai Clinical Research and Trial Center , , ,","place":["Shanghai, China, 201203"]},{"name":"ShanghaiTech University , , ,","place":["Shanghai, China, 201210"]},{"name":"Zhongshan Hospital Fudan University , , ,","place":["Shanghai, China, 200032"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"1","key":"2026090707082190500_cit1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102406","article-title":"Evolving Global\nEtiology of Hepatocellular Carcinoma (HCC): Insights and Trends for\n2024","volume":"15","author":"Koshy","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"3","key":"2026090707082190500_cit2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","article-title":"Hepatocellular carcinoma:\nmolecular mechanism, targeted therapy,\nand biomarkers","volume":"42","author":"Wang","year":"2023","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"2026090707082190500_cit3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-Specific\nAntibody Drug Conjugates Targeting Hepatocellular Carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"2026090707082190500_cit4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.824208","article-title":"Glypican-3: A Novel\nand Promising Target for the Treatment of Hepatocellular Carcinoma","volume":"12","author":"Zheng","year":"2022","journal-title":"Front. Oncol."},{"issue":"15","key":"2026090707082190500_cit5","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3\nT-Cell\nTherapy for Advanced Hepatocellular Carcinoma: Results of Phase I\nTrials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"2026090707082190500_cit6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","article-title":"Progress and\nChallenges in Glypican-3\nTargeting for Hepatocellular Carcinoma Therapy","volume":"28","author":"Couzinet","year":"2024","journal-title":"Expert Opin. Ther. Targets."},{"issue":"1","key":"2026090707082190500_cit7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1039\/C8BM01016A","article-title":"An innovative peptide with high affinity to\nGPC3 for hepatocellular carcinoma diagnosis","volume":"7","author":"Zhang","year":"2019","journal-title":"Biomater Sci."},{"issue":"7","key":"2026090707082190500_cit8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.122.265171","article-title":"Site-Specifically Conjugated\nSingle-Domain Antibody Successfully Identifies Glypican-3-Expressing\nLiver Cancer by Immuno-PET","volume":"64","author":"Fayn","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090707082190500_cit9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: A promising\nbiomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"1","key":"2026090707082190500_cit10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084807","article-title":"Disulfiram eradicates\ntumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent\nand -independent manners","volume":"9","author":"Chiba","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"2026090707082190500_cit11","first-page":"7255","article-title":"BEZ235 enhances chemosensitivity of paclitaxel\nin hepatocellular carcinoma through inhibiting the PI3K\/Akt\/mTOR pathway","volume":"11","author":"Liu","year":"2019","journal-title":"Am. J. Transl Res."},{"issue":"8","key":"2026090707082190500_cit12","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ymthe.2019.04.020","article-title":"Combined Antitumor Effects\nof Sorafenib and\nGPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma","volume":"27","author":"Wu","year":"2019","journal-title":"Mol. Ther."},{"issue":"410","key":"2026090707082190500_cit13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3\nbispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"2026090707082190500_cit14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates\nof clinical response and resistance to atezolizumab in combination\nwith bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"issue":"10","key":"2026090707082190500_cit15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","article-title":"Progress and\nchallenges in glypican-3\ntargeting for hepatocellular carcinoma therapy","volume":"28","author":"Couzinet","year":"2024","journal-title":"Expert Opin. Ther. Targets."},{"issue":"8047","key":"2026090707082190500_cit16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured\nGPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"5","key":"2026090707082190500_cit17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2967\/jnumed.113.132118","article-title":"Glypican-3-targeted\n89Zr PET imaging of hepatocellular carcinoma","volume":"55","author":"Sham","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026090707082190500_cit18","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2967\/jnumed.114.145102","article-title":"Glypican-3-targeting\nF(ab\u2019)2 for 89Zr PET of hepatocellular carcinoma","volume":"55","author":"Sham","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"25","key":"2026090707082190500_cit19","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1016\/j.biomaterials.2014.04.089","article-title":"Imaging of hepatocellular carcinoma patient-derived\nxenografts using 89Zr-labeled anti-glypican-3 monoclonal\nantibody","volume":"35","author":"Yang","year":"2014","journal-title":"Biomaterials"},{"issue":"2","key":"2026090707082190500_cit20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00726-017-2517-z","article-title":"Imaging the expression\nof glypican-3 in hepatocellular carcinoma by PET","volume":"50","author":"Wang","year":"2018","journal-title":"Amino Acids"},{"issue":"20","key":"2026090707082190500_cit21","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1039\/D0BM00943A","article-title":"The development of a\nGlypican-3-specific binding peptide using in vivo and in vitro two-step\nphage display screening for the PET imaging of hepatocellular carcinoma","volume":"8","author":"Qin","year":"2020","journal-title":"Biomater. Sci."},{"issue":"8","key":"2026090707082190500_cit22","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s00259-022-05723-x","article-title":"GPC3-targeted immunoPET\nimaging of hepatocellular carcinomas","volume":"49","author":"An","year":"2022","journal-title":"Eur. J.\nNucl. Med. Mol. Imaging"},{"issue":"4","key":"2026090707082190500_cit23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide Binder to Glypican-3\nas a Theranostic Agent for Hepatocellular Carcinoma","volume":"65","author":"Lin","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026090707082190500_cit24","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.124.268147","article-title":"[68Ga]Ga-RAYZ-8009:\nA Glypican-3-Targeted Diagnostic Radiopharmaceutical for Hepatocellular\nCarcinoma Molecular Imaging-A First-in-Human Case Series","volume":"65","author":"Poot","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"18","key":"2026090707082190500_cit25","doi-asserted-by":"publisher","first-page":"19714","DOI":"10.1021\/acs.jmedchem.5c02081","article-title":"10P3Me: A GPC3-Targeted\nPeptide PET Probe for Subcutaneous and Orthotopic HCC Imaging","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00559","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4710\/66378528\/acs.molpharmaceut.6c00559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4710\/66378528\/acs.molpharmaceut.6c00559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:29:42Z","timestamp":1788780582000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4710\/5242147\/Preclinical-Evaluation-of-68Ga-Ga-CS03-as-a-Novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,3]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00559","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00559.s001","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}